| Literature DB >> 24729886 |
Huimin Yan1, Antonio Prista2, Sushant M Ranadive1, Albertino Damasceno3, Paula Caupers3, Jill A Kanaley4, Bo Fernhall5.
Abstract
Background. Exercise training intervention is underused in the management of type 2 diabetes mellitus in East Africa. Methods. 41 physically-active males with type 2 diabetes mellitus living in Mozambique were recruited and randomly assigned to 12 weeks of supervised exercise of low intensity exercise (LEX), vigorous intensity exercise (VEX), or to a control group (CON). Since there were no differences for any outcome variables between the exercise groups, VEX and LEX were combined into one exercise group (EX). Results. Age and baseline body weight were similar between EX and CON. Plasma glucose at 120 min following glucose load (Glu 120) was significantly reduced in the EX group after training (Glu 120 : 17.3 mmol/L to 15.0 mmol/L, P < 0.05), whereas Glu 120 remained unchanged in the CON (Glu 120 : 16.6 mmol/L to 18.7 mmol/L). After controlling for baseline blood pressure (BP), posttraining systolic BP and diastolic BP were lower in the EX group than in the CON group (EX: 129/77 mm Hg, CON: 152/83 mm Hg, P < 0.05). Conclusion. Adding exercise to already active African men with type 2 diabetes improved glucose control and BP levels without concomitant changes in weight.Entities:
Year: 2014 PMID: 24729886 PMCID: PMC3960729 DOI: 10.1155/2014/864897
Source DB: PubMed Journal: ISRN Endocrinol ISSN: 2090-4630
A summary of medications.
| EX | CON | Classification | |
|---|---|---|---|
| Nifedipine | 0 (0) | 1 (10) | antihypertensive |
| Amiloride | 8 (20) | 3 (30) | antihypertensive |
| Hydrochlorothiazide | 16 (39) | 6 (60) | antihypertensive |
| Methyldopa | 4 (10) | 0 (0) | antihypertensive |
| Enalapril | 12 (29) | 1 (10) | antihypertensive |
| Chlorthalidone | 3 (7) | 0 (0) | antihypertensive |
| Metformin | 13 (32) | 3 (30) | antidiabetic |
| Glyburide | 25 (61) | 6 (60) | antidiabetic |
| Atenolol | 1 (2) | 1 (10) | antihypertensive |
Numbers are expressed as count (percentage within this group).
Many subjects were on multiple medications.
Comparison between EX and CON at baseline and after intervention.
| EX | CON | |||
|---|---|---|---|---|
| Baseline | Post | Baseline | Post | |
| Age | 53 ± 2 | — | 55 ± 3 | — |
| Height | 170.0 ± 1.2 | — | 170.3 ± 1.3 | — |
| Weight (kg)# | 78.8 ± 2.4 | 79.7 ± 2.4 | 78.4 ± 4.3 | 79.7 ± 4.3 |
| BMI# | 27.2 ± 0.7 | 27.4 ± 0.7 | 27.0 ± 1.3 | 27.5 ± 1.3 |
| Waist circumference (cm) | 95.8 ± 2.2 | 94.2 ± 1.9 | 95.1 ± 3.7 | 95.0 ± 2.2 |
| Hip circumference (cm) | 99.7 ± 1.5 | 98.7 ± 1.5 | 98.9 ± 2.6 | 98.2 ± 2.6 |
| SBP (mmHg) | 131 ± 3‡ | 129 ± 4§ | 145 ± 6 | 152 ± 6 |
| DBP (mmHg) | 80 ± 1‡ | 77 ± 2§ | 80 ± 3 | 83 ± 3 |
| Plasma glucose (mmol/L) | 10.3 ± 0.9 | 9.6 ± 0.7 | 9.0 ± 1.5 | 11.1 ± 1.3 |
| HbA1c (%)# | 8.8 ± 0.5 | 7.7 ± 0.4 | 8.4 ± 0.9 | 7.7 ± 0.8 |
| Time on treadmill (min)* | 10.7 ± 0.7 | 12.4 ± 0.8† | 9.8 ± 1.7 | 9.6 ± 1.8 |
| VO2 max (mL/kg/min) | 23.1 ± 1.0 | 25.0 ± 1.3 | 21.6 ± 2.5 | 22.5 ± 3.0 |
| Chest skinfold (cm)# | 19.3 ± 1.4 | 14.8 ± 1.0† | 21.8 ± 3.0 | 16.2 ± 2.1 |
| Abdominal skinfold (cm) | 22.7 ± 1.2 | 22.8 ± 1.5 | 21.3 ± 2.6 | 23.0 ± 3.2 |
| Thigh skinfold (cm)* | 16.3 ± 1.3 | 14.1 ± 1.5† | 15.8 ± 2.7 | 16.2 ± 3.0 |
| Total skinfold (cm)# | 59.0 ± 3.2 | 52.4 ± 3.4† | 58.9 ± 3.4 | 55.4 ± 7.0 |
Note: values are mean ± SEM;
VO2 max: maximal aerobic capacity;
BMI: body mass index;
*P < 0.05 interaction effect; # P < 0.05 time effect; § P < 0.05 between EX and CON after covarying for baseline; ‡ P < 0.05 between EX and CON; † P < 0.05 between baseline and post in EX.
Figure 1Plasma glucose at 120 min during oral glucose tolerance test at baseline and postintervention in EX and CON groups. *P < 0.05 interaction effect; ‡ P < 0.05 between EX and CON.
Figure 2Changes of HbA1c was significantly correlated with (a) changes of SBP (P < 0.05) and (b) changes of DBP (P < 0.05) after intervention.